StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma operating margin

Operating margin is operating income as a percentage of revenue.

Matinas BioPharma's operating margin for the twelve months ending Dec 31, 2023 was -2168.4%. For fiscal 2023 it was -2168.4%, against -771.3% the year before. The highest annual figure on record is -771.3% in fiscal 2022.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-2168.4%−1397.1
FY2022Dec 31, 2022-771.3%+74183.2
FY2021Dec 31, 2021-74954.5%−59666.2
FY2020Dec 31, 2020-15288.4%+5779.0
FY2019Dec 31, 2019-21067.4%−8836.4
FY2018Dec 31, 2018-12230.9%−1206.3
FY2017Dec 31, 2017-11024.6%−5928.6
FY2015Dec 31, 2015-5096.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2023Mar 31, 2023-509.7%+18549.8
Q4 FY2022Dec 31, 2022-515.5%+9866.7
Q3 FY2022Sep 30, 2022-513.8%+5334.5
Q2 FY2022Jun 30, 2022-557.4%+4476.1
Q1 FY2021Mar 31, 2021-19059.5%−15268.4
Q4 FY2020Dec 31, 2020-10382.2%+3382.5
Q3 FY2020Sep 30, 2020-5848.3%+4463.4
Q2 FY2019Jun 30, 2019-5033.5%+2556.4
Q2 FY2018Jun 30, 2018-3791.1%+5063.6
Q1 FY2018Mar 31, 2018-13764.7%+16212.0
Q4 FY2017Dec 31, 2017-10311.7%–
Q3 FY2017Sep 30, 2017-7589.8%–
Q2 FY2017Jun 30, 2017-8854.7%–
Q1 FY2017Mar 31, 2017-29976.8%–

More Matinas BioPharma figures

See a number that looks wrong?